Stephan Christgau, PhD joined Novo A/S in September 2007 as Investment Director of Novo Seeds. Prior to joining Novo Seeds, Dr. Christgau was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. Previously, Dr. Christgau has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S. Dr. Christgau is the author of more than 60 scientific publications and inventor on more than 30 patent families.
Leadership